Dostarlimab for Rectal Cancer: FDA Approval and USMLE Review

The FDA has approved the PD-1 inhibitor Jemperli (dostarlimab-gxly) for certain adults with previously untreated stage 2 or 3 rectal cancer. The tumor must have a broken DNA mismatch repair system, confirmed by a lab test. For some of these patients, the drug may replace the usual sequence of chemotherapy, radiation, and surgery. The approval is accelerated and rests on early data, so the long-term picture is still unclear.

What happened

The FDA approved dostarlimab for adults with stage 2 or stage 3 rectal cancer that has not yet been treated. At these stages, the cancer has grown into nearby tissue or lymph nodes but has not reached other organs.

The approval is limited to a specific tumor type. A lab test must show that the tumor's DNA repair system, which normally catches and fixes copying errors, is defective. Mistakes then accumulate, and the cancer becomes easier for the immune system to recognize. According to the FDA, only a small share of rectal cancers have this trait.

The decision was based on early results from a trial of 154 patients. They received dostarlimab by IV every three weeks for six months, up to nine doses. After more than two years of follow-up, nearly 3 in 4 patients had gone without surgery, radiation, or chemotherapy, the FDA said.

An earlier study at Memorial Sloan Kettering Cancer Center gave the drug to 50 patients. None showed signs of cancer after treatment. Among 27 people tracked for at least three years, the cancer came back in only one, per the FDA.

The agency used its accelerated approval program, which lets promising drugs reach patients sooner based on early data. GSK, the manufacturer, must keep following patients to show the benefit lasts.

Why it matters

The usual approach to locally advanced rectal cancer often starts with chemotherapy and radiation, then surgery. These treatments can cause lasting problems with bowel, bladder, and sexual function, and they can affect fertility. Some patients end up with a permanent colostomy.

The FDA's Oncology Center of Excellence director, Dr. Angelo de Claro, called the approval "a groundbreaking option that avoids surgery, radiation and chemotherapy" for certain types of rectal cancer.

The approval is also a clear example of biomarker-driven oncology. The treatment is chosen by the tumor's molecular features, not only by its location and stage. That is why the news fits so well with the USMLE themes of DNA repair, tumor immunology, and checkpoint inhibitor pharmacology.

What to know for the USMLE — high-yield bullet list

• Mismatch repair (MMR) fixes base-pair mismatches and small insertion/deletion loops made during DNA replication. The key proteins are MLH1, MSH2, MSH6, and PMS2. MutS-type proteins (MSH2/MSH6) recognize the mismatch, and MutL-type proteins (MLH1/PMS2) coordinate repair.
• dMMR (deficient mismatch repair) leads to microsatellite instability (MSI-H). Errors build up in short repeat sequences, the mutation burden is high, and tumors produce many neoantigens. They are often rich in tumor-infiltrating lymphocytes, which helps explain their sensitivity to checkpoint blockade.
• Lynch syndrome (HNPCC) is an autosomal dominant germline defect in an MMR gene. It raises the risk of colorectal and endometrial cancer, plus ovarian, gastric, urinary tract, and other cancers. Most sporadic dMMR colon cancers come instead from MLH1 promoter hypermethylation, often alongside a BRAF V600E mutation. The news source does not say how many patients in the trials had Lynch syndrome, so do not assume it.
• Colorectal carcinogenesis has two classic pathways. The adenoma–carcinoma sequence (APC → KRAS → p53, with chromosomal instability) accounts for most cases. The MSI pathway is driven by MMR defects.
• PD-1 is a receptor on activated T cells. When tumor cells express PD-L1 and engage it, T-cell receptor signaling is dampened, and the T cell becomes "exhausted." Blocking this interaction releases the brake on the antitumor T-cell response.
• Dostarlimab is a humanized monoclonal antibody against PD-1. Related drugs include pembrolizumab, nivolumab, and cemiplimab (PD-1), and atezolizumab, durvalumab, and avelumab (PD-L1). Ipilimumab targets CTLA-4, which acts earlier, at T-cell priming.
• Immune-related adverse events are a classic exam topic. They include colitis, pneumonitis, hepatitis, thyroiditis/hypothyroidism, hypophysitis, adrenal insufficiency, new-onset type 1 diabetes, and skin reactions. The mechanism is loss of self-tolerance, and severe cases are generally managed with corticosteroids. Dostarlimab's adverse events were not described in this news source.
• Rectal cancer staging and standard care: stage 2 generally means invasion through the muscularis propria (T3–T4) without nodal spread. Stage 3 means lymph node involvement. The standard approach is neoadjuvant chemoradiation followed by total mesorectal excision. Surgical options include low anterior resection and abdominoperineal resection, which requires a permanent colostomy.
• Testing: universal tumor testing for MMR proteins by immunohistochemistry or for MSI by PCR is the usual way to identify dMMR/MSI-H tumors. Loss of staining for an MMR protein points to the affected gene.

Limitations

• Early data. The FDA based its decision on early results. Follow-up of just over two years is short for a cancer where recurrence can appear later.
• Accelerated approval. This pathway exists because the data are promising but not final. GSK must keep tracking patients to show that the benefits last. The source states plainly that it is unknown how often the cancer may return over the long term.
• Not everyone avoids standard treatment. "Nearly 3 in 4" means roughly one in four patients in the 154-patient trial did not avoid all three standard therapies. The source does not detail what happened to those patients.
• Small earlier study. The Memorial Sloan Kettering results come from 50 patients, and only 27 had been followed for at least three years. One recurrence in 27 is encouraging, but the sample is small.
• Narrow population. The drug is approved only for tumors with the DNA repair defect, which the FDA says is a small share of rectal cancers. The results do not apply to most rectal cancers.
• Source and context. The source material does not describe a comparison group or report survival data against standard therapy. Quotes from GSK representatives and a GSK spokesperson reflect the manufacturer's perspective. A single patient story is an anecdote, not evidence.

This article is educational and is not treatment advice. Eligibility and treatment decisions belong with a patient's oncology team and the official prescribing information.

FAQ

What is dostarlimab (Jemperli)?

It is an immunotherapy that blocks the PD-1 receptor on T cells. This helps the immune system recognize and attack tumor cells. In this approval, it is given by IV every three weeks for six months, up to nine doses.

Who is the new FDA approval for?

It covers adults with untreated stage 2 or 3 rectal cancer whose tumors have deficient DNA mismatch repair, confirmed by a lab test. The FDA says only a small share of rectal cancers have this feature.

Does this mean chemotherapy, radiation, and surgery are obsolete for rectal cancer?

No. The approval applies to a small, molecularly defined group. Even in the trial, not every patient avoided all three treatments. The approval is accelerated, and long-term recurrence rates are still unknown.

Key takeaways

• The FDA granted accelerated approval to dostarlimab for untreated stage 2–3 rectal cancer with deficient mismatch repair. In a 154-patient trial, nearly 3 in 4 patients avoided surgery, radiation, and chemotherapy after more than two years of follow-up.
• For the USMLE, connect the dots: MMR gene defect → MSI-H → high neoantigen load → PD-1 blockade works. Remember Lynch syndrome and the immune-related adverse events of checkpoint inhibitors.
• The data are early, and the durability of benefit is unproven. GSK must keep following patients, and the approval applies only to a narrow, biomarker-defined group.